Marek Wrobel

Novy Jicin, MO, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.

Journal: Blood cancer journal

Published: April 19, 2023

Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.

Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.

Journal: Neoplasma

Published: August 13, 2022

Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.

Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.

Journal: European journal of haematology

Published: April 03, 2021

Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation.

Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation.

Journal: International journal of laboratory hematology

Published: August 17, 2020

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Journal: Cancer medicine

Published: April 30, 2018

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.

Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.

Journal: Current medical research and opinion

Published: November 28, 2017

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.

Journal: European journal of haematology

Published: April 07, 2017

Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.

Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.

Journal: European journal of haematology

Published: April 29, 2016

Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.

Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.

Journal: PloS one

Published: December 19, 2014

10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.

10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.

Journal: Leukemia research

Published: April 13, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026